Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05046899
Other study ID # BioC002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 14, 2021
Est. completion date June 13, 2022

Study information

Verified date October 2022
Source Biocool AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.


Description:

After being informed about the investigation and the potential risks, all subjects giving written informed consent will undergo screening to determine eligibility for study entry. At week 0, subjects who meet the eligibility requirements will be randomised in open, intra-patient investigation, treated with BIOpH+ Psoriasis Medical Bath on one side, and comparative treatment on the other side for 8 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date June 13, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Voluntary agreed to participation and has duly signed Informed Consent Form - Males and females = 18 years of age - In the Investigator's opinion, the patient is not likely to become pregnant during study participation (e.g. in a same-sex relationship, not sexually active, sterile, not of child-bearing age, uses contraception, etc.) - Subject diagnosed with stable mild-moderate plaque psoriasis, defined by PASI = 9 - Intra-individual difference between left and right hemi-body PASI scores not > 1.0 - Patients with symmetrical psoriasis Exclusion Criteria: - Presence of other forms of psoriasis other than psoriasis vulgaris (palmoplantar psoriasis, inverse psoriasis, other forms of hyperkeratosis) - Use of systemic/biological treatment for psoriasis - Known hypersensitivity or allergy to study products - Any serious medical condition that could interfere with the evaluation of study results - Poor compliance in other investigational study, as assessed by investigator - Pregnant, breastfeeding, or planning to become pregnant during study - Patients with alcohol -or drug abuse - Any other conditions as judged by the investigator may make the follow-up or investigation inappropriate - Anyone unsuitable to participate as subject according to the Declaration of Helsinki

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BIOpH+ Psoriasis Medical Bath
20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
Cetaphil Moisturizing Lotion
Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.

Locations

Country Name City State
Sweden Avdelningen för klinisk prövning Örebro

Sponsors (1)

Lead Sponsor Collaborator
Biocool AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Psoriasis Area and Severity Index (PASI) score from Baseline compared to week 8. The PASI score is a validated, investigator instrument assessing the severity of psoriasis. The severity is combined with the percentage of affected area. Baseline and week 8.
Secondary Dermatology Life Quality Index (DLQI) A quality of life instrument and will evaluate how much the skin problems affects the study subject's daily life. It is a 10-question questionnaire. Each question contains four response categories: 0=not at all, 1=a little, 2=a lot, and 3=very much. A higher score means worse outcome. Baseline and week 8.
Secondary Psoriasis Area Severity Index (PASI) It combines the severity (erythema, induration and desquamation) and percentage of affected area. A high score means worse outcome.
The body is divided into 4 sections:
Head, weight = 0.1
Arms, weight = 0.2
Trunk, weight = 0.3
Legs, weight = 0.4
For each section, the percent of area of skin involved is estimated and graded:
0. 0% of involved area
<10% of involved area
10-29% of involved area
30-49% of involved area
50-69% of involved area
70-89% of involved area
90-100% of involved area Within each area, the severity is estimated for 3 clinical signs: erythema (redness), induration (thickness) and desquamation (scaling). Severity is measured on a scale from 0-4, from none to maximum.
The sum of all 3 severity parameters is calculated for each body section, multiplied by the area score for that area, and multiplied for the weight of the body section, for a maximum score of 72.
Week 2 and week 4
Secondary Physician Global Assessment (PGA) The Physician Global Assessment, is a 5-point scoring system that will be used to assess the overall disease severity. This treatment response on each visit will be scored: 0 =cleared, 1=almost clear, 2=mild 3=moderate, and 4=severe. A higher scores mean worse outcome. Baseline, week 2, 4, and 8
Secondary Tolerability assessment Tolerability assessment completed by the study subject about local tolerance regarding experience of pruritus and burning/stinging measured on a 5-point scale, or by questions to be answered with yes or no. Week 2, 4 and week 8.
Secondary Usability /satisfaction assessments A questionnaire to be answered by study subject about investigational device usability and satisfaction measured on a 5-point scale, or by questions to be answered with yes or no. Week 8
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2